BACKGROUND: Treatment with opioid agonists is effective for opioid use disorder, but early discontinuation of treatment is a major obstacle to success. Intensive longitudinal methods - which take many repeated measurements over time, usually in the field- have provided unique insight into the effects of stress, mood and craving on drug use while people are being treated; these methods might also be useful for studying the processes that lead people to drop out of treatment. METHODS: Ecological momentary assessment (EMA) was conducted for up to 17 weeks by obtaining multiple electronic diary entries per day from 238 participants being treated with methadone or buprenorphine-naloxone. Survival analysis was used to study two outcomes: dropping out of treatment and noncompliance with EMA self-report requirements. Self-reports of stress, craving, and mood were used as time-varying predictors. Demographic and psychosocial variables measured with the Addiction Severity Index at the start of treatment were used as time-invariant predictors. RESULTS: Dropping out of treatment was more likely in participants with more reported hassles (a measure of stress), higher levels of cocaine craving, lower levels of positive mood, a recent history of emotional abuse, a recent history of being bothered frequently by psychological problems, and with buprenorphine rather than methadone as their medication. In contrast, study noncompliance was not significantly associated with any of the variables analyzed. CONCLUSIONS: Assessment of stress, craving and mood during treatment might identify people who are at greater risk of dropping out, and therapeutic interventions targeting these processes might increase retention. Published by Elsevier B.V.
BACKGROUND: Treatment with opioid agonists is effective for opioid use disorder, but early discontinuation of treatment is a major obstacle to success. Intensive longitudinal methods - which take many repeated measurements over time, usually in the field- have provided unique insight into the effects of stress, mood and craving on drug use while people are being treated; these methods might also be useful for studying the processes that lead people to drop out of treatment. METHODS: Ecological momentary assessment (EMA) was conducted for up to 17 weeks by obtaining multiple electronic diary entries per day from 238 participants being treated with methadone or buprenorphine-naloxone. Survival analysis was used to study two outcomes: dropping out of treatment and noncompliance with EMA self-report requirements. Self-reports of stress, craving, and mood were used as time-varying predictors. Demographic and psychosocial variables measured with the Addiction Severity Index at the start of treatment were used as time-invariant predictors. RESULTS: Dropping out of treatment was more likely in participants with more reported hassles (a measure of stress), higher levels of cocaine craving, lower levels of positive mood, a recent history of emotional abuse, a recent history of being bothered frequently by psychological problems, and with buprenorphine rather than methadone as their medication. In contrast, study noncompliance was not significantly associated with any of the variables analyzed. CONCLUSIONS: Assessment of stress, craving and mood during treatment might identify people who are at greater risk of dropping out, and therapeutic interventions targeting these processes might increase retention. Published by Elsevier B.V.
Authors: William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Ashley P Kennedy; Udi E Ghitza; Daniel A Agage; John P Schmittner; David H Epstein; Kenzie L Preston Journal: Am J Psychiatry Date: 2015-03-17 Impact factor: 18.112
Authors: Kenzie L Preston; William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; David H Epstein Journal: Psychopharmacology (Berl) Date: 2017-06-08 Impact factor: 4.530
Authors: Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman Journal: Drug Alcohol Depend Date: 2008-05-27 Impact factor: 4.492
Authors: Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Sharon M Kelly; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz Journal: J Subst Abuse Treat Date: 2013-04-05
Authors: Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe Journal: J Psychoactive Drugs Date: 2015 Apr-Jun
Authors: Samuel W Stull; Jeremiah W Bertz; Leigh V Panlilio; William J Kowalczyk; Karran A Phillips; Landhing M Moran; Jia-Ling Lin; Massoud Vahabzadeh; Patrick H Finan; Kenzie L Preston; David H Epstein Journal: J Abnorm Psychol Date: 2021-07
Authors: Lisa A Marsch; Aimee Campbell; Cynthia Campbell; Ching-Hua Chen; Emre Ertin; Udi Ghitza; Chantal Lambert-Harris; Saeed Hassanpour; August F Holtyn; Yih-Ing Hser; Petra Jacobs; Jeffrey D Klausner; Shea Lemley; David Kotz; Andrea Meier; Bethany McLeman; Jennifer McNeely; Varun Mishra; Larissa Mooney; Edward Nunes; Chrysovalantis Stafylis; Catherine Stanger; Elizabeth Saunders; Geetha Subramaniam; Sean Young Journal: J Subst Abuse Treat Date: 2020-03
Authors: Garrett James Jenkins; Michael J Cleveland; Kyler Scott Knapp; Scott C Bunce; H Harrington Cleveland Journal: Addict Behav Date: 2020-09-24 Impact factor: 3.913
Authors: Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche Journal: J Dual Diagn Date: 2021-09-28
Authors: Albert J Burgess-Hull; Kirsten E Smith; Destiny Schriefer; Leigh V Panlilio; David H Epstein; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2021-06-25 Impact factor: 4.852